DCGONasdaqServices-Health ServicesFiscal year ends December 31
DocGo Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$0.25−0.02 (-6.11%)
Close on Oct 19, 2026
- Market cap
- $25.18M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
–
Operating margin
-55.3%−39.6 pts over 5 years
Net margin
-56.6%−40.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -47.7% | -9.9% | +27.9% | – | |
| Free cash flow | -55.0% | +5.2% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -78.5% | |
| Return on assets | – | – | -54.2% | |
| Current ratio | – | 2.49 | 2.26 | |
| Debt to equity | – | 0.01 | 0.00 | |
| Net debt to EBITDA | – | 3.66× | 0.31× | |
| Interest coverage | – | -931.2× | – | |
| Capex to revenue | – | 4.6% | 1.4% | |
| Diluted shares | – | 58M | 99M |
Where the cash went
Fiscal 2021 to 2025, five years combined
DocGo generated $199.88M from operations and spent $51.79M on capital expenditure, dividends and share buybacks. 45% of that went back into the business.
Generated
$199.88M
Used
$51.79M
Capital expenditure$23.48M45%Dividends$00%Share buybacks$28.32M55%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-56.6%
×Asset turnover0.96×
×Equity multiplier1.45×
=Return on equity, FY2025-78.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -56.6% | 0.96× | 1.45× | -78.5% |
| FY2024 | 3.2% | 1.30× | 1.52× | 6.4% |
| FY2023 | 1.1% | 1.41× | 1.54× | 2.4% |
| FY2022 | 7.9% | 1.25× | 1.43× | 14.0% |
| FY2021 | 7.4% | 1.56× | 1.49× | 17.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$182.40M
- Cash generatingOperating cash flow above zero$34.45M
- Return on assets improvedROA up on the prior year4.1% → -40.0%
- Earnings backed by cashOperating cash flow above net income$34.45M vs -$182.40M
- Less leverageLong-term debt to assets fell0.0% → 0.1%
- Better liquidityCurrent ratio rose2.50 → 2.26
- No dilutionShare count did not rise109M → 99M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.26 → 0.71